US4784856A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Percutaneous pharmaceutical preparation
Assignee: Sekisui Chemical Co Ltd
•
Filing: 1987-08-10
•
Granted: 1988-11-15
•
Expires: 2007-08-10
Abstract
Abstract A percutaneous administration type pharmaceutical preparation in tape form comprising a flexible backing, which is not permeable by the active ingredient, and an adhesive base layer formed on said flexible backing; said adhesive base layer consisting essentially of an adhesive base material and an active ingredient compatible with said adhesive base material, wherein said adhesive base material is a copolymer containing 2-ethylhexyl acrylate (EHA) in a concentration of 45 mole% or more and N-vinyl-2-pyrrolidone (VP) in a concentration of 20 to 55 mole%, and said active ingredient is isosorbide dinitrate (ISDN) which is contained in a concentration of 10% by weight or more in said adhesive base material.
Inventors
- 👤 Mutsumi Fukuda
- 👤 Takashi Nakagawa
- 👤 Takaji Kishi
- 👤 Michiharu Ando
- 👤 Masahachi Yoshioka
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 14:36
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K9/7061; A61L; A61L15/00; A61L15/16; A61L15/42; A61L15/58
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
203 words
A percutaneous administration type pharmaceutical preparation in tape form comprising a flexible backing, which is not permeable by the active ingredient, and an adhesive base layer formed on said flexible backing; said adhesive base layer consisting essentially of an adhesive base material and an active ingredient compatible with said adhesive base material, wherein said adhesive base material is a copolymer containing 2-ethylhexyl acrylate (EHA) in a concentration of 45 to 80 mole %, a (meth)acrylate monomer in a concentration of 0 to 35 mole %, which is at least one selected from the group consisting of propyl acrylate, butyl acrylate, hexyl acrylate, 2-ethyy butyl acrylate, heptyl acrylate, octyl acrylate, nonyl acrylate, decyl methacrylate, and lauryl methacrylate, and N-vinyl-2-pyrrolidone (VP) in a concentration of 20 to 55 mole %, with the sum of the mole % of EHA, (meth)acrylate and VP being 100, and with the EHA/VP ratio by mole % being in the range from 80/20 to 45/55, and said active ingredient is isosorbide dinitrate (ISDN) which is contained in a concentration of 13 to 30% by weight in said adhesive base material and in a concentration of 80 to 100% of the saturated solubility concentration of ISDN in said adhesive base material.
Claim 2
Dependent Claim
203 words
A percutaneous administration type pharmaceutical preparation in tape form comprising a flexible backing, which is not permeable by the active ingredient, and an adhesive base layer formed on said flexible backing; said adhesive base layer consisting essentially of an adhesive base material and an active ingredient compatible with said adhesive base material, wherein said adhesive base material is a copolymer containing 2-ethylhexyl acrylate (EHA) in a concentration of 45 to 80 mole %, a (meth)acrylate monomer in a concentration of 0 to 35 mole %, which is at least one selected from the group consisting of propyl acrylate, butyl acrylate, hexyl acrylate, 2-ethyy butyl acrylate, heptyl acrylate, octyl acrylate, nonyl acrylate, decyl methacrylate, and lauryl methacrylate, and N-vinyl-2-pyrrolidone (VP) in a concentration of 20 to 55 mole %, with the sum of the mole % of EHA, (meth)acrylate and VP being 100, and with the EHA/VP ratio by mole % being in the range from 80/20 to 45/55, and said active ingredient is isosorbide dinitrate (ISDN) which is contained in a concentration of 13 to 30% by weight in said adhesive base material and in a concentration of 80 to 100% of the saturated solubility concentration of ISDN in said adhesive base material.
Claim 3
Dependent Claim
112 words
The pharmaceutical preparation according to claim 1, wherein said adhesive base material is a copolymer containing EHA in a concentration of 55 to 70 mole %, a (meth)acrylate monomer in a concentration of 0 to 15 mole % and VP in a concentration of 30 to 45 mole %, with the sum of the mole % of EHA, (meth)acrylate and VP being 100, and with the EHA/VP ratio by mole % being in the range from 70/30 to 55/45, and the concentration of ISDN in said adhesive base material is 13 to 25% by weight and is 80 to 100% of the saturated solubility concentration of ISDN in said adhesive base material.
Claim 4
Dependent Claim
53 words
The pharmaceutical preparation according to claim 1, wherein said adhesive base material is a copolymer containing a (meth)acrylate monomer in a concentration of 0.005 to 0.5% by weight of the total amount of monomers therein, said (meth)acrylate multifunctional monomer being at least one selected from the group consisting of di(meth)acrylates, tri(meth)acrylates and tetra(meth)acrylates.
Claim 5
Dependent Claim
19 words
The pharmaceutical preparation according to claim 1 wherein said adhesive base material is a copolymer containing no (meth)acrylate monomer.
Claim 6
Dependent Claim
15 words
The pharmaceutical preparation according to claim 3, wherein said multifunctional (meth)acrylate monomer is of di(meth)acrylates.
Claim 7
Dependent Claim
21 words
The pharmaceutical preparation according to claim 1, wherein the concentration of ISDN in said adhesive base material is 22% by weight.
Claim 8
Dependent Claim
21 words
The pharmaceutical preparation according to claim 1, wherein the concentration of ISDN in said adhesive base material is 24% by weight.
Claim 9
Dependent Claim
21 words
The pharmaceutical preparation according to claim 1, wherein the concentration of ISDN in said adhesive base material is 26% by weight.
Claim 10
Dependent Claim
21 words
The pharmaceutical preparation according to claim 1, wherein the concentration of ISDN in said adhesive base material is 28% by weight.
Claim 11
Dependent Claim
21 words
The pharmaceutical preparation according to claim 1, wherein the concentration of ISDN in said adhesive base material is 30% by weight.
Claim 12
Dependent Claim
36 words
A pharmaceutical preparation according to claim 2, wherein said adhesive base material is a copolymer containing a multifunctional (meth)acrylate monomer in a concentration of 0.005 to 0.5% by weight of the total amount of monomers therein.
Claim 13
Dependent Claim
19 words
The pharmaceutical preparation according to claim 2, wherein said adhesive base material is a copolymer containing no (meth)acrylate monomer.
Claim 14
Dependent Claim
15 words
The pharmaceutical preparation according to claim 11, wherein said multifunctional (meth)acrylate monomer is of di(meth)acrylates.
References Cited (Backward Citations)
DE2216260A1
Cited
DE2636559A1
Cited
US4073291A
Cited
EP0024107A1
Cited
US4310509A
Cited
EP0062682A1
Cited
US4390520A
Cited
EP0054279A2
Cited
US4482534A
Cited
FR2497457A1
Cited
US4420470A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-11-15 | 1992-05-16 | 1992-11-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-11-15 | 1996-05-16 | 1996-11-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-11-15 | 2000-05-16 | 2000-11-15 | $7700.00 | Window Closed / Lapsed |